Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

Dear Dr. Roach: I’m a 78-year-old man with a stent and a blockage in one of the arteries to my heart. I am on a low-fat diet and take ramipril for cholesterol. My levels are very good (total ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Depending on one’s perspective, the anti-inflammatory colchicine is either an unsung and underprescribed drug for patients with cardiovascular disease, or it’s an agent with limited clinical benefit ...

WASHINGTON, DC – OCTOBER 29, 2024 – The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce ...

DEAR DR. ROACH: I’m a 78-year-old man with a stent and a blockage in one of the arteries to my heart. I am on a low-fat diet and take ramipril for cholesterol. My levels are very good (total ...

(Boston)—Gout is the most common form of inflammatory arthritis, with worldwide prevalence of approximately four%. The accumulation of monosodium urate crystals in gout leads to the clinical ...

Please provide your email address to receive an email when new articles are posted on . More than 25% of patients with gout who use colchicine prophylaxis were on potentially interacting medications.

The colchicine-binding domain (CBD) of tubulin, one of the earliest identified regulatory sites, remains underexplored in oncology despite its proven success in other therapeutic areas. Drugs ...